Clinical Trial Update: Efficacy of Infliximab in the Treatment of Patients Affected by Corticodependent Crohn's Disease (P02732) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating infliximab for cortico-dependent Crohn's disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Infliximab (infliximab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Crohn's Disease | Phase 3 | Status: TERMINATED